Biomedit
biomedit.com
Actively hiring
Food & Beverages
Microbiome
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$16M
1 round on record
Latest round
$16M
Venture round · Apr 2025 · 17 mo ago
Team
22
US Form 5500 (plan participants) · Dec 2024
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2025 | $16M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | BiomEdit, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Bruce SchelkopfExecutive OfficerSEC Form D
Aaron SchachtExecutive Officer, DirectorSEC Form D
Similar startupsby what they do, their industry and backers
AMILI runs Southeast Asia's first gut microbiome bank and offers microbiome testing and therapeutic research. Its data addresses the…
At BugBiome, our mission is to create safer pest control solutions by harnessing natural microbiomes through our high-throughput screening…
Outpost builds AI models of the human microbiome so drug, food, and ingredient R&D teams can predict microbiome interactions and flag risks…
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome…
We do women’s wellness differently. Get clinically-studied support for your vagina, gut, and hormones — powered by your microbiome.
Effortless, science-backed oral microbiome insights from saliva. Decode your saliva for personalized wellness.
News
BiomEdit Acquires Folium Science To Expand Programmable Veterinary Biologics
BiomEdit, an animal health biotechnology company, has acquired Folium Science's technology platform and pipeline assets, including BiomElix One, a poultry feed additive approved in Brazil. The transaction adds an approved product asset and a complementary
Read more
Report
BiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics Capabilities
FOR IMMEDIATE RELEASE BiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics Capabilities Transaction adds CRISPR-based precision microbiome technology and BiomElix One, a poultry feed additive approved
Read more
Report
BiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics Capabilities
BiomEdit, a pioneering animal health biotechnology company, today announced it has acquired Folium Science
Read more
Report
Pro access
Upgrade to see all 21 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Bruce Schelkopf
Executive Officer
Aaron Schacht
Executive Officer, Director
Patrick James
Director
Paul Casady
Director
Brett Wong
Director
Barbara Bodem
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Fishers
United States
HQ
Greenfield
United States
Regional office
Contact details
2710 Innovation Way, Greenfield, IN 46140
Financials
Total raised
$16M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $16M | Details |